secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2024-04-19T23:59:59+00:00
Accession:  0001193125-24-101292
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase 201 trial ~75% enrolled; expects completion by mid-June 2024
-----------------------------------------------------------------------

- 201 Trial (risvodetinib) ~75% enrolled, 30 patients left; enrollment completion expected mid-June 2024.
- Plan to initiate a 12-month extension study; requires additional capital.
- Pre-IND meeting with FDA for IkT-001Pro in PAH completed; pre-NDA for cancer indications held.
- Submitted grants to NINDS/NIH for biomarker development including new monoclonal antibody.
- Expects end-of-Phase 2 meeting with FDA by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524101292/0001193125-24-101292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524101292/d826079d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-101292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer